Immuron (Germany) Today
| ANW Stock | EUR 0.04 0.00 0.00% |
PerformanceWeak
| Odds Of DistressLow
|
Immuron is trading at 0.039 as of the 26th of February 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.039. Immuron has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. Immuron Limited was founded in 1994 and is based in Carlton, Australia. The company has 227.8 M outstanding shares. More on Immuron Limited
Moving against Immuron Stock
Immuron Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Immuron's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immuron or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Immuron Limited (ANW) is traded on Frankfurt Exchange in Germany and employs 5 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immuron's market, we take the total number of its shares issued and multiply it by Immuron's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Immuron Limited classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 227.8 M outstanding shares.
Immuron Limited has accumulated about 26.44 M in cash with (3.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immuron Probability Of Bankruptcy
Ownership AllocationImmuron Limited has a total of 227.8 Million outstanding shares. Immuron retains 18.08 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immuron Ownership Details
Immuron Limited Risk Profiles
Although Immuron's alpha and beta are two of the key measurements used to evaluate Immuron's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.76 | |||
| Semi Deviation | 5.43 | |||
| Standard Deviation | 7.83 | |||
| Variance | 61.26 |
Immuron Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Immuron without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Immuron Corporate Management
Elected by the shareholders, the Immuron's board of directors comprises two types of representatives: Immuron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immuron. The board's role is to monitor Immuron's management team and ensure that shareholders' interests are well served. Immuron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immuron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA | Chief Officer | Profile | |
| BBus CA | CFO Sec | Profile | |
| Jerry Kanellos | Chief Officer | Profile | |
| Dan Peres | Chief Officer | Profile | |
| Flavio Palumbo | Chief Officer | Profile | |
| David Lyon | Head Marketing | Profile |
Other Information on Investing in Immuron Stock
Immuron financial ratios help investors to determine whether Immuron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immuron with respect to the benefits of owning Immuron security.